transparent gif
ImmuneSupport.com Home  
Type 2 Diabetes In the Genes
Fibromyalgia & Chronic Fatigue Syndrome Home Page Fibromyalgia & Chronic Fatigue Syndrome Library Fibromyalgia & Chronic Fatigue Syndrome Treatment and Research Email bulletins Fibromyalgia & Chronic Fatigue Syndrome Products Fibromyalgia & Chronic Fatigue Syndrome Community Area Fibromyalgia & Chronic Fatigue Syndrome About Us transparent gif transparent gif
transparent gif
Health Watch Newsletter background The Latest News Articles background The Latest Abstracts background The Latest Drug News background
Search Our Site
 
Home
Fibromyalgia Resources

Chronic Fatigue Syndrome Resources

E-mail Bulletin
Store
Community
About Us

Your Support Funds Research & Advocacy

Type 2 Diabetes In the Genes


by Editor
ImmuneSupport.com


02-22-2007

Advertisement

“Overeating and physical inactivity are major causes of type 2 diabetes mellitus, but they affect only genetically susceptible individuals… [and]…recent research has suggested that specific genes may be associated with the risk of developing the disease,” writes the Editor of the international science journal Nature.

The comment refers to a suite of articles in that journal’s February 7, 2007 issue highlighting the emerging study of connections between variation in the human genome and factors such as diet in the development “of most common diseases.”

One study featured in this issue – “A genome-wide association study identifies novel risk loci for type 2 diabetes” (see abstract, below) – reports on identification of four previously unknown genes as risk factors for diabetes 2, and confirms the previously identified association with a gene referred to as TCF7L2.

The researchers postulate that this constellation of genes likely contributes significantly to diabetes 2 risk, and that further study to better understand their function – along with modified diet and exercise – should support development of new concepts in treatment.

Following is an abstract of the article.

A genome-wide association study identifies novel risk loci for type 2 diabetes

By R Sladek, et al

Journal: Nature. 2007 February 11. [E-pubication ahead of print.]

Authors and affiliations: R Sladek, G Rocheleau, J Rung, C Dina, L Shen, D Serre, P Boutin, D Vincent, A Belisle, S Hadjadj, B Balkau, B Heude, G Charpentier, TJ Hudson, A Montpetit, AV Pshezhetsky, M Prentki, BI Posner, DJ Balding, D Meyre, C Polychronakos, Philippe Froguel. Departments of Human Genetics, Medicine, McGill University; Genome Quebec Innovation Centre, Montreal, Canada.

PMID: 17293876

Type 2 diabetes mellitus results from the interaction of environmental factors with a combination of genetic variants [polymorphisms], most of which were hitherto unknown. A systematic search for these variants was recently made possible by the development of high-density arrays that permit the genotyping of hundreds of thousands of polymorphisms.

We tested 392,935 single-nucleotide polymorphisms in a French case-control cohort. Markers with the most significant difference in genotype frequencies between cases of type 2 diabetes and controls were fast-tracked for testing in a second cohort.

This identified four loci containing variants that confer type 2 diabetes risk, in addition to confirming the known association with the TCF7L2 gene.

These loci include a non-synonymous polymorphism in the zinc transporter SLC30A8, which is expressed exclusively in insulin-producing beta-cells, and two linkage disequilibrium blocks that contain genes potentially involved in beta-cell development or function (IDE-KIF11-HHEX and EXT2-ALX4).

These associations explain a substantial portion of disease risk and constitute proof of principle for the genome-wide approach to the elucidation of complex genetic traits.

_________

Note: The full text of this article is available for a fee from the publisher, at www.nature.com/nature/journal/v445/n7130/edsumm/e070222-09.html

  Newsletter SignUp Discuss (0 comments) Email Article Print Page
Related Articles:
National Institutes of Health Announces CFS Research Funding Opportunity Workshop - Sept 17, Rockville, MD
Rating of 2.9
CDC data released June 8 put Chronic Fatigue Syndrome prevalence in the state of Georgia at 2.54% of those ages 18 to 59
Rating of 2.9
Whole-Genome ME/CFS Study Resumes: Recruits Subjects
Rating of 3
Computerized cuff pressure algometry: A new method to assess deep-tissue hypersensitivity in Fibromyalgia
Rating of 3
The Role of Infection in Initiating ME/CFS
Rating of 3.1

Every purchase funds research, donations and the community resources provided within our website.

Guaifenesin
Extended Release, Fast Acting, Ultra Pure. Used in Dr. St Amand Protocol.
ImmuneSupport.com


New Energy NADH
Increase mental sharpness, energy, concentration. Stimulant free NADH.
ImmuneSupport.com


B-12 Extreme
Most potent single dose of B-12. Increase energy & mental clarity.
ImmuneSupport.com


Green Tea Mega EGCG Boost your immune system & protect cells from damage. 290mg EGCG.
ImmuneSupport.com


Neptune Krill Oil
For optimal omega-3 absorption. 100% pure.
ImmuneSupport.com


Fuel Your Energy
CorvalenM with D-Ribose, magnesium & malic acid.
ImmuneSupport.com


At ProHealth we believe in "commerce with compassion."

Weekly Special





[ Be the first to comment on this article ]
DISCUSS THIS ARTICLE  (0 existing comments)
Post a Comment
transparent gif
transparent gif transparent gif transparent gif

Home | Library | Email Bulletins | Store | Community | Affiliates


ProHealth's ImmuneSupport.com- The World's Largest Fibromyalgia & Chronic Fatigue Syndrome Website!
Email US or Call US at 1-800-366-6056
Monday-Friday, 7 a.m.-5 p.m. PST
International Callers can reach us at 001.805.564.3064
Copyright © 2008 ProHealth, Inc.
About us, Affiliates, Careers, Contact us, Privacy, 30-day Money Back Guarantee